CN108783457B - Preparation method and application of coreopsis tinctoria extract containing echinacoside - Google Patents
Preparation method and application of coreopsis tinctoria extract containing echinacoside Download PDFInfo
- Publication number
- CN108783457B CN108783457B CN201810653577.0A CN201810653577A CN108783457B CN 108783457 B CN108783457 B CN 108783457B CN 201810653577 A CN201810653577 A CN 201810653577A CN 108783457 B CN108783457 B CN 108783457B
- Authority
- CN
- China
- Prior art keywords
- echinacoside
- coreopsis tinctoria
- extract
- coreopsis
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 235000005912 Coreopsis cardaminifolia Nutrition 0.000 title claims abstract description 81
- 239000000284 extract Substances 0.000 title claims abstract description 81
- FSBUXLDOLNLABB-ISAKITKMSA-N echinacoside Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](OC(=O)\C=C\C=2C=C(O)C(O)=CC=2)[C@@H](CO[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)O[C@@H](OCCC=2C=C(O)C(O)=CC=2)[C@@H]1O FSBUXLDOLNLABB-ISAKITKMSA-N 0.000 title claims abstract description 70
- NJYVDFDTLLZVMG-UHFFFAOYSA-N echinacoside Natural products CC1OC(OC2C(O)C(OCCc3ccc(O)c(O)c3)OC(COC4OC(CO)C(O)C(O)C4O)C2OC(=O)C=Cc5cc(O)cc(O)c5)C(O)C(O)C1O NJYVDFDTLLZVMG-UHFFFAOYSA-N 0.000 title claims abstract description 65
- 238000002360 preparation method Methods 0.000 title claims abstract description 20
- 241000132544 Coreopsis tinctoria Species 0.000 title abstract 8
- 230000000968 intestinal effect Effects 0.000 claims abstract description 25
- 230000001105 regulatory effect Effects 0.000 claims abstract description 14
- 238000001035 drying Methods 0.000 claims abstract description 9
- 235000013376 functional food Nutrition 0.000 claims abstract description 7
- 244000128583 Coreopsis cardaminifolia Species 0.000 claims description 73
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 28
- 239000000243 solution Substances 0.000 claims description 22
- 241000723353 Chrysanthemum Species 0.000 claims description 16
- 235000007516 Chrysanthemum Nutrition 0.000 claims description 16
- 244000308760 Helichrysum petiolatum Species 0.000 claims description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 6
- 238000005303 weighing Methods 0.000 claims description 5
- XPVYZIHUAHTXGV-UHFFFAOYSA-N 22, 23-Dihydro-(3beta, 5alpha, 6beta, 22E)-Cholesta-7, 22-diene-3, 5, 6-triol, 9CI Natural products CC12CCC(C(=O)OC)=CCC1C(CC(=O)OC)CC2OC1OC(CO)C(O)C(O)C1O XPVYZIHUAHTXGV-UHFFFAOYSA-N 0.000 claims description 4
- 238000010992 reflux Methods 0.000 claims description 4
- 239000011347 resin Substances 0.000 claims description 4
- 229920005989 resin Polymers 0.000 claims description 4
- 238000000605 extraction Methods 0.000 claims description 3
- 238000001914 filtration Methods 0.000 claims description 3
- 230000003472 neutralizing effect Effects 0.000 claims description 3
- 238000007670 refining Methods 0.000 claims description 3
- QMVODIKHHIRSGI-RWGOFXMDSA-N (e)-3-(3,4-dihydroxyphenyl)-1-[2-hydroxy-4-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyphenyl]prop-2-en-1-one Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC(C=C1O)=CC=C1C(=O)\C=C\C1=CC=C(O)C(O)=C1 QMVODIKHHIRSGI-RWGOFXMDSA-N 0.000 claims 1
- QMVODIKHHIRSGI-UHFFFAOYSA-N 4'-beta-D-glucopyranosyloxy-3,4,2'-trihydroxy-trans-chalcone Natural products OC1C(O)C(O)C(CO)OC1OC(C=C1O)=CC=C1C(=O)C=CC1=CC=C(O)C(O)=C1 QMVODIKHHIRSGI-UHFFFAOYSA-N 0.000 claims 1
- BVGZTRWADYNRBE-UHFFFAOYSA-N Coreopsin Natural products OCC1OC(Oc2ccc(C=CC(=O)c3ccc(O)cc3O)cc2O)C(O)C(O)C1O BVGZTRWADYNRBE-UHFFFAOYSA-N 0.000 claims 1
- 238000010790 dilution Methods 0.000 claims 1
- 239000012895 dilution Substances 0.000 claims 1
- 208000030159 metabolic disease Diseases 0.000 abstract description 5
- 206010020772 Hypertension Diseases 0.000 abstract description 3
- 201000001421 hyperglycemia Diseases 0.000 abstract description 3
- 201000005577 familial hyperlipidemia Diseases 0.000 abstract 1
- 239000008280 blood Substances 0.000 description 15
- 210000004369 blood Anatomy 0.000 description 15
- 239000000523 sample Substances 0.000 description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 238000011160 research Methods 0.000 description 9
- 238000006243 chemical reaction Methods 0.000 description 8
- 229930182470 glycoside Natural products 0.000 description 8
- 239000002207 metabolite Substances 0.000 description 8
- 241000723366 Coreopsis Species 0.000 description 7
- -1 aglycon glucuronide Chemical class 0.000 description 7
- 239000012488 sample solution Substances 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 230000036772 blood pressure Effects 0.000 description 6
- 238000004128 high performance liquid chromatography Methods 0.000 description 6
- 230000004060 metabolic process Effects 0.000 description 6
- 239000012071 phase Substances 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 241000700159 Rattus Species 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 229930003935 flavonoid Natural products 0.000 description 5
- 150000002215 flavonoids Chemical class 0.000 description 5
- 235000017173 flavonoids Nutrition 0.000 description 5
- 210000001035 gastrointestinal tract Anatomy 0.000 description 5
- 150000002338 glycosides Chemical class 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- TWCMVXMQHSVIOJ-UHFFFAOYSA-N Aglycone of yadanzioside D Natural products COC(=O)C12OCC34C(CC5C(=CC(O)C(O)C5(C)C3C(O)C1O)C)OC(=O)C(OC(=O)C)C24 TWCMVXMQHSVIOJ-UHFFFAOYSA-N 0.000 description 4
- PLMKQQMDOMTZGG-UHFFFAOYSA-N Astrantiagenin E-methylester Natural products CC12CCC(O)C(C)(CO)C1CCC1(C)C2CC=C2C3CC(C)(C)CCC3(C(=O)OC)CCC21C PLMKQQMDOMTZGG-UHFFFAOYSA-N 0.000 description 4
- 235000005881 Calendula officinalis Nutrition 0.000 description 4
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- 240000000785 Tagetes erecta Species 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- PFOARMALXZGCHY-UHFFFAOYSA-N homoegonol Natural products C1=C(OC)C(OC)=CC=C1C1=CC2=CC(CCCO)=CC(OC)=C2O1 PFOARMALXZGCHY-UHFFFAOYSA-N 0.000 description 4
- 241000196324 Embryophyta Species 0.000 description 3
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 3
- 208000031226 Hyperlipidaemia Diseases 0.000 description 3
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 3
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 229930003944 flavone Natural products 0.000 description 3
- 235000011949 flavones Nutrition 0.000 description 3
- 229930182486 flavonoid glycoside Natural products 0.000 description 3
- 150000007955 flavonoid glycosides Chemical class 0.000 description 3
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 3
- 229940097043 glucuronic acid Drugs 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 239000011259 mixed solution Substances 0.000 description 3
- 239000008055 phosphate buffer solution Substances 0.000 description 3
- 239000002504 physiological saline solution Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 238000001269 time-of-flight mass spectrometry Methods 0.000 description 3
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 3
- 241000186000 Bifidobacterium Species 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 241000186660 Lactobacillus Species 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 210000003608 fece Anatomy 0.000 description 2
- 238000003304 gavage Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 210000002429 large intestine Anatomy 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000000419 plant extract Substances 0.000 description 2
- 230000035484 reaction time Effects 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 210000000813 small intestine Anatomy 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- DKVBOUDTNWVDEP-NJCHZNEYSA-N teicoplanin aglycone Chemical compound N([C@H](C(N[C@@H](C1=CC(O)=CC(O)=C1C=1C(O)=CC=C2C=1)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)OC=1C=C3C=C(C=1O)OC1=CC=C(C=C1Cl)C[C@H](C(=O)N1)NC([C@H](N)C=4C=C(O5)C(O)=CC=4)=O)C(=O)[C@@H]2NC(=O)[C@@H]3NC(=O)[C@@H]1C1=CC5=CC(O)=C1 DKVBOUDTNWVDEP-NJCHZNEYSA-N 0.000 description 2
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- CWVRJTMFETXNAD-FWCWNIRPSA-N 3-O-Caffeoylquinic acid Natural products O[C@H]1[C@@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-FWCWNIRPSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- 241000566693 Asteriscus Species 0.000 description 1
- 235000018860 Betula potaninii Nutrition 0.000 description 1
- 244000104272 Bidens pilosa Species 0.000 description 1
- 235000010662 Bidens pilosa Nutrition 0.000 description 1
- 208000027796 Blood pressure disease Diseases 0.000 description 1
- PZIRUHCJZBGLDY-UHFFFAOYSA-N Caffeoylquinic acid Natural products CC(CCC(=O)C(C)C1C(=O)CC2C3CC(O)C4CC(O)CCC4(C)C3CCC12C)C(=O)O PZIRUHCJZBGLDY-UHFFFAOYSA-N 0.000 description 1
- DQFBYFPFKXHELB-UHFFFAOYSA-N Chalcone Natural products C=1C=CC=CC=1C(=O)C=CC1=CC=CC=C1 DQFBYFPFKXHELB-UHFFFAOYSA-N 0.000 description 1
- 235000008495 Chrysanthemum leucanthemum Nutrition 0.000 description 1
- 244000192528 Chrysanthemum parthenium Species 0.000 description 1
- 235000000604 Chrysanthemum parthenium Nutrition 0.000 description 1
- 208000036649 Dysbacteriosis Diseases 0.000 description 1
- 208000027244 Dysbiosis Diseases 0.000 description 1
- 244000016296 Jacobaea maritima Species 0.000 description 1
- UBORTCNDUKBEOP-UHFFFAOYSA-N L-xanthosine Natural products OC1C(O)C(CO)OC1N1C(NC(=O)NC2=O)=C2N=C1 UBORTCNDUKBEOP-UHFFFAOYSA-N 0.000 description 1
- CWVRJTMFETXNAD-KLZCAUPSSA-N Neochlorogenin-saeure Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O CWVRJTMFETXNAD-KLZCAUPSSA-N 0.000 description 1
- 208000031964 Other metabolic disease Diseases 0.000 description 1
- SYYHBUHOUUETMI-UHFFFAOYSA-N Pennogenin Natural products O1C2CC3C4CC=C5CC(O)CCC5(C)C4CCC3(C)C2(O)C(C)C21CCC(C)CO2 SYYHBUHOUUETMI-UHFFFAOYSA-N 0.000 description 1
- 241001145025 Saussurea involucrata Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- UBORTCNDUKBEOP-HAVMAKPUSA-N Xanthosine Natural products O[C@@H]1[C@H](O)[C@H](CO)O[C@H]1N1C(NC(=O)NC2=O)=C2N=C1 UBORTCNDUKBEOP-HAVMAKPUSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 235000005513 chalcones Nutrition 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- CWVRJTMFETXNAD-JUHZACGLSA-N chlorogenic acid Chemical compound O[C@@H]1[C@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-JUHZACGLSA-N 0.000 description 1
- 229940074393 chlorogenic acid Drugs 0.000 description 1
- FFQSDFBBSXGVKF-KHSQJDLVSA-N chlorogenic acid Natural products O[C@@H]1C[C@](O)(C[C@@H](CC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O FFQSDFBBSXGVKF-KHSQJDLVSA-N 0.000 description 1
- 235000001368 chlorogenic acid Nutrition 0.000 description 1
- BMRSEYFENKXDIS-KLZCAUPSSA-N cis-3-O-p-coumaroylquinic acid Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)cc2)[C@@H]1O)C(=O)O BMRSEYFENKXDIS-KLZCAUPSSA-N 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 239000000287 crude extract Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000003113 dilution method Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000007140 dysbiosis Effects 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 235000008384 feverfew Nutrition 0.000 description 1
- 150000002212 flavone derivatives Chemical class 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 229930182480 glucuronide Natural products 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000000055 hyoplipidemic effect Effects 0.000 description 1
- 230000007365 immunoregulation Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229940039696 lactobacillus Drugs 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000009630 liquid culture Methods 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000037323 metabolic rate Effects 0.000 description 1
- 239000002032 methanolic fraction Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 235000015816 nutrient absorption Nutrition 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000004792 oxidative damage Effects 0.000 description 1
- SYYHBUHOUUETMI-WJOMMTHPSA-N pennogenin Chemical compound C([C@@]12[C@H]([C@@]3([C@@]4(C)CC[C@@H]5[C@@]6(C)CC[C@H](O)CC6=CC[C@H]5[C@@H]4C[C@@H]3O2)O)C)C[C@@H](C)CO1 SYYHBUHOUUETMI-WJOMMTHPSA-N 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 235000013406 prebiotics Nutrition 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000004704 ultra performance liquid chromatography Methods 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- UBORTCNDUKBEOP-UUOKFMHZSA-N xanthosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(NC(=O)NC2=O)=C2N=C1 UBORTCNDUKBEOP-UUOKFMHZSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Botany (AREA)
- Mycology (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
The invention discloses a preparation method of a coreopsis tinctoria extract containing echinacoside and application of the coreopsis tinctoria extract in preparing functional food for regulating intestinal flora functions and metabolic diseases. The preparation method of the coreopsis tinctoria extract comprises the steps of taking a coreopsis tinctoria extract solution containing marroside, adjusting the pH value to be 5-14, preserving heat for a certain time at 30-100 ℃, adjusting the pH value to be 3-5, concentrating and drying to obtain the coreopsis tinctoria extract. The coreopsis tinctoria extract contains echinacoside component, and is obtained by converting maritin. The coreopsis tinctoria extract has certain intestinal flora regulating effect, and can be used in functional food for regulating hyperlipemia, hypertension, and hyperglycemia metabolic diseases.
Description
Technical Field
The invention belongs to the field of medicines and functional foods, relates to a preparation method and application of a coreopsis tinctoria extract containing echinacoside, and particularly relates to a coreopsis tinctoria extract containing echinacoside and application of the coreopsis tinctoria extract in preparation of medicines for treating intestinal dysbacteriosis and metabolic diseases such as hyperlipidemia, hypertension and hyperglycemia.
Background
Coreopsis tinctoria Nutt, a feverfew, is a flower of Coreopsis tinctoria, a native north america of the plant commonly known as "Coreopsis tinctoria" in the area of the honda, also known as "Coreopsis tinctoria", alpine chrysanthemum, Coreopsis, and a vitamin, which is called "guliqiyi". Snow chrysanthemum is drunk as a special scented tea in folks in the area, and is considered to have the effects of reducing blood pressure, blood sugar and blood fat. With the understanding and popularization of the efficacy of the medicinal material, snow chrysanthemum is known as Xinjiang specialty with the same name of Tianshan saussurea involucrata and is subjected to large-scale planting, popularization and application.
The existing research data show that the coreopsis tinctoria has the more definite efficacies of reducing blood sugar, blood fat, blood pressure and other metabolic diseases, which is consistent with the folk application experience of the coreopsis tinctoria. Recent research reports prove that the coreopsis tinctoria and polyphenol components such as flavone and chlorogenic acid in the coreopsis tinctoria have multiple specific efficacies of reducing blood sugar, blood pressure and blood fat, resisting oxidative damage and the like [ panying and the like, the research on chemical components and pharmacological activity of coreopsis plants is advanced, modern medicines and clinics, 2012 and 27 (5): 521]. The diverse intestinal flora forms a micro-ecosystem in the intestinal tract, participates in the metabolism of nutrient and functional components in food, can directly participate in and influence the processes of various health and diseases such as nutrient absorption, growth and development, immunoregulation, biological barrier and the like of the organism, and becomes a hotspot of international research in recent years. Previous researches of the inventor show that the coreopsis tinctoria total flavonoids and the components such as marioside and flavonomoside in the coreopsis tinctoria total flavonoids have better lipid regulating effect [ Gaofei, the hypolipidemic effect and the mechanism research of the coreopsis tinctoria total flavonoids, a Master academic thesis of Suzhou university, 2016], but whether coreopsis tinctoria has the intestinal flora regulating effect and whether other unknown in-vivo active components exist or not are required to be further deeply researched.
Disclosure of Invention
The invention aims to: a preparation method and application of coreopsis tinctoria extract containing echinacoside solve the above technical problems.
The invention has a technical scheme that:
provides a preparation method of a coreopsis tinctoria extract of echinacoside, which comprises the following steps: obtaining a maroside-containing snow chrysanthemum primary extract solution, adjusting the pH value to 5-14, preserving the temperature at 30-100 ℃ for 0.5-10 h, neutralizing until the pH value is 3-5, concentrating, and drying to obtain a sea chrysanthemum glycoside-containing snow chrysanthemum extract.
Further, uniformly mixing the coreopsis tinctoria extract containing echinacoside with the maroside-containing coreopsis tinctoria primary extract solution, and drying to obtain a coreopsis tinctoria extract mixed solution containing echinacoside.
Further, echinacoside in the plains coreopsis extract containing echinacoside is obtained by converting marigold.
Further, the preparation method of the senecio cineraria initial extract solution containing the maroside comprises the following steps: weighing dried coreopsis tinctoria flower, performing reflux extraction for 2 times by using 75% ethanol which is 20 times of the amount of the coreopsis tinctoria flower, performing 1 hour each time, combining extracting solutions of the two times, filtering, performing reduced pressure concentration to recover ethanol, adding a proper amount of water to dilute, refining by using an AB-8 resin column, performing sample loading, sequentially eluting by using water and 75% ethanol, collecting 75% ethanol eluting parts, concentrating, and drying to obtain a coreopsis tinctoria primary extract solution containing marroside.
Furthermore, in the marroside-containing snow chrysanthemum primary extract solution, the content of the marroside is more than 10%, in the sea chrysanthemum extract containing the sea chrysanthemum glycoside, the content of the sea chrysanthemum glycoside is 5-50%, and the snow chrysanthemum extract containing the sea chrysanthemum glycoside contains the xanthosine and the marroside.
Further, adjusting the pH value to 6-12, and preserving the temperature at 35-80 ℃ for 0.5-10 h.
The other technical scheme of the invention is as follows: application of coreopsis tinctoria extract containing echinacoside in preparing functional food for regulating intestinal flora and functional food for treating hyperlipidemia, hypertension and hyperglycemia metabolic diseases.
The invention has the advantages that:
(1) the coreopsis tinctoria extract containing echinacoside contains echinacoside which is one of endogenous active ingredients in coreopsis tinctoria and is converted from marigold, so that the function of regulating blood fat of coreopsis tinctoria can be better exerted, and the coreopsis tinctoria extract containing echinacoside can be applied to preparation of medicines for treating hyperlipidemia and resisting oxidation;
(2) compared with the common coreopsis tinctoria extract in the prior art, the coreopsis tinctoria extract containing echinacoside has the advantages of stable chemical composition, high purity of pharmacological active ingredients, stable effect and small dosage of medicaments;
(3) the pennogenin, the maliside and the echinacoside in the coreopsis extract can be metabolized by intestinal flora to generate corresponding aglycon, aglycon glucuronide and aglycon sulfate, so that the coreopsis extract is utilized by the intestinal flora and has the beneficial effects of regulating blood fat, reducing blood sugar, reducing blood pressure and the like.
Drawings
In order to more clearly illustrate the technical solutions of the embodiments of the present invention, the drawings needed to be used in the description of the embodiments will be briefly introduced below, and it is obvious that the drawings in the following description are only some embodiments of the present invention, and it is obvious for those skilled in the art to obtain other drawings based on these drawings without inventive exercise. Wherein the content of the first and second substances,
FIG. 1 is a high performance liquid chromatogram of a sample of a Helichrysum extract containing echinacoside prepared by the present invention;
wherein chromatographic peaks 1-3 are Marinoside (1), echinacoside (2) and xanthoside (3) in sequence.
FIG. 2 is a high performance liquid chromatogram of the conversion of Marigoside (1) to echinacoside (2) in example 2.
Detailed Description
The invention aims to obtain a coreopsis tinctoria extract containing echinacoside, which is prepared by adopting the following method: taking a coreopsis tinctoria primary extract solution containing maroside, adjusting the pH to 5-14, keeping the temperature at 30-100 ℃ for a certain time, neutralizing until the pH is 3-5, concentrating, and drying to obtain a coreopsis tinctoria extract containing echinacoside; or adding echinacoside (such as extract of coreopsis tinctoria containing echinacoside) into the crude extract of coreopsis tinctoria containing maroside, mixing, and drying to obtain mixed solution of extract of coreopsis tinctoria containing echinacoside.
The mixed solution of the coreopsis tinctoria extract containing echinacoside and the coreopsis tinctoria extract containing echinacoside is an extract containing echinacoside, and the extract is obtained by converting maritin. The content of the surfactant can be 1-95% according to requirements. Preferably, the echinacoside content is 5-50%, and it can contain xanthoside and maliside.
The Coreopsis plant extract is obtained from Coreopsis plant, and can be selected from flower and stem and leaf of the plant, and the Coreopsis plant extract contains Marilioside, preferably Marilioside content is greater than 10%, or can be further refined Marilioside extract. Of these, the flower of Coreopsis tinctoria Nutt (Coreopsis tinctoria) is preferable. The extract can be obtained by conventional solvent extraction and macroporous resin refining. Such as those available in the open literature.
In the preparation process of the coreopsis tinctoria extract containing echinacoside, the coreopsis tinctoria extract solution can be selected from water and a solution containing an organic solvent, the pH value range is preferably 6-12, the temperature range is preferably 35-80 ℃, the temperature is kept, and the reaction time range is preferably 0.5-10 h, so that the dissolution of the coreopsis tinctoria extract and the conversion of maritin are promoted. Among these, the agents for adjusting the pH may be optional conventional acids and bases, preferably inorganic, such as: sodium hydroxide, potassium hydroxide, sodium carbonate, sodium bicarbonate and hydrochloric acid, sulfuric acid, acetic acid, and the like.
In the process of researching the preparation process of the coreopsis tinctoria extract, the invention unexpectedly discovers that the marroside (1) in the coreopsis tinctoria extract can be converted into a small amount of the flavonoliside (3) and another unknown new metabolite under neutral and weakly alkaline heat preservation and heating conditions such as artificial intestinal juice (pH 6.8; 37 ℃). Further separation and identification confirm that the new metabolite is echinacoside (2). The experimental research shows that the echinacoside does not exist in the natural medicinal material of the snow chrysanthemum, but can be detected in the intestinal tract of experimental animals to find that the echinacoside is one of the in vivo active ingredients converted from the marigold. The present invention has been completed through intensive studies. The chemical reaction principle of the preparation method is as follows, wherein Glc is glucosyl:
in order to make the aforementioned objects, features and advantages of the present invention comprehensible, embodiments accompanied with figures are further described below. The invention is not limited to the embodiments listed but also comprises any other known variations within the scope of the invention as claimed.
First, reference herein to "one embodiment" or "an embodiment" means that a particular feature, structure, or characteristic described in connection with the embodiment is included in at least one implementation of the invention. The appearances of the phrase "in one embodiment" in various places in the specification are not necessarily all referring to the same embodiment, nor are separate or alternative embodiments mutually exclusive of other embodiments.
The present invention is described in detail by using the schematic structural diagrams, etc., and for convenience of illustration, the schematic diagrams are not enlarged partially according to the general scale when describing the embodiments of the present invention, and the schematic diagrams are only examples, which should not limit the scope of the present invention. In addition, the actual fabrication process should include three-dimensional space of length, width and depth.
Example 1: preparation of Helichrysum extract containing echinacoside (I)
100g of dried Coreopsis tinctoria (batch 130501 of Xinjiang Daban city, N.J.) is extracted by 2L of 75% ethanol under reflux for 2 times, 1h each time, the extracting solutions of the two times are combined, filtered, decompressed, concentrated and recycled to ethanol, added with a proper amount of water to be diluted to 300mL, refined by an AB-8 resin column, eluted by water 6BV and 75% ethanol 4BV in sequence after sample loading, the eluted part of the 75% ethanol is collected, concentrated and dried to obtain the Coreopsis tinctoria primary extract (CTE, 12.2g, batch 20160720). Separating Maririside (1) and flavone glycoside (3) from CTE by C18 reverse phase silica gel column chromatography.
Weighing CTE 25mg, adding ethanol to fix the volume to 5 ml; respectively putting 0.4ml into an EP (European patent publication) tube, respectively adding 1.6ml of phosphate buffer solution with pH6.8 or artificial intestinal juice (prepared according to 2015 version of Chinese pharmacopoeia), uniformly mixing by vortex, incubating at 37 +/-0.5 ℃ for 24h, and respectively sampling 0.1ml at preset time points of 0, 2, 4, 8, 12 and 24h to obtain the helichrysum extract (CTH) sample solution containing the echinacoside. The CTH sample solution was diluted to 1ml with methanol and assayed by HPLC.
And (4) HPLC detection: using an Agilent 1260 high performance liquid chromatography system, a Cosmosil 5C18-AR-II column (4.6mm × 250mm, 5 μm), gradient elution with 0.1% acetic acid as mobile phase a and acetonitrile as mobile phase B: 0-12min, 16% B; 12-30min, 16% -30% B; 30-40min, 30% -90% B; detection wavelength: 280nm (flavonolicosides), 378nm (malinosides and echinacosides); the column temperature is 30 ℃; the flow rate is 1ml min < -1 >; the injection volume was 20. mu.L.
As a result: HPLC detection shows that the contents of Maririside and Huangnuomalin in CTE are respectively 18.3% and 25.6%. In the CTH sample solution, the content of echinacoside (2) is increased along with the prolonging of the incubation time, and the content of mariside (1) is correspondingly reduced. The test results of the pilot-prepared CTH-1 sample (8h) are shown in FIG. 1, and the content of marroside, echinacoside and flavonolide in the sample is respectively 9.3%, 31.2% and 6.5%.
Through further research, the Marigoside can be converted into echinacoside under neutral and alkaline conditions of CTE, and the water extract of coreopsis tinctoria can also be selected for direct conversion reaction. Wherein, the pH value is preferably 6-10, the temperature range is preferably 35-80 ℃, the reaction time range is preferably 0.5-10 h, and the purpose is to promote the dissolution of the coreopsis tinctoria extract and the conversion of the maritin. Among them, the agent for adjusting pH may be an optional conventional acid and base, among which inorganic substances such as sodium hydroxide, potassium hydroxide, sodium carbonate, sodium bicarbonate and hydrochloric acid, sulfuric acid, acetic acid, and the like are preferable.
Example 2: preparation of Helichrysum extract containing echinacoside (II)
In this example, mariroside obtained from a first extract of coreopsis tinctoria was used as a raw material to further study the conversion reaction product and its mechanism.
Weighing Marigold 25mg, adding ethanol to constant volume of 5 ml; respectively taking 0.4ml of the Mariin metabolite sample solution, respectively adding 1.6ml of phosphate buffer solution with the pH value of 6.8 or artificial intestinal juice (prepared according to 2015 version of Chinese pharmacopoeia), uniformly mixing by vortex, incubating at 37 +/-0.5 ℃ for 24h, and respectively sampling 0.1ml at preset time points of 0, 2, 4, 6, 8 and 24 h.
As a result: the results are shown in FIG. 2. Through HPLC quantitative analysis, in the marioside metabolite sample solution, marioside (1) is quantitatively converted into echinacoside (2), and the conversion is basically complete within 24 h. In addition, the marroside is partially converted into the flavone glycoside (3) at the same time 2-6h from the beginning of the reaction.
Purification and structural identification of echinacoside (2): weighing 100mg of maliside, adding into phosphate buffer solution with pH of 6.8, reacting in water bath at 37 ℃ for 24h at constant temperature, moderately concentrating the reaction solution, separating with C18 reverse phase chromatographic column (100ml/BV), eluting with 25%, 30%, 32%, 34%, 42% and 75% methanol at 4BV respectively, combining and concentrating 32% -34% methanol fractions, and drying to obtain metabolite 2 which is orange powder. (-) -ESI/TOFMS gives [ M-H]-447.0929 (theoretical calculation 447.0927) and corresponding molecular formula C21H20O11。1H NMR(600MHz,DMSO-d6):δ7.47(1H,d,J＝1.8Hz,H-2'),7.34(1H,dd,J＝8.2,1.8Hz,H-6'),7.21(1H,d,J＝8.4Hz,H-4),7.07(1H,d,J＝8.4Hz,H-5),6.87(1H,d,J＝8.2Hz,H-5'),6.72(1H,s,H-10),4.95(1H,d,J＝7.7Hz,H-1")。13C NMR(150MHz,DMSO-d6):δ182.48(C-3),154.11(C-8),152.33(C-6),148.43(C-4'),145.65(C-2),145.60(C-3'),132.45(C-7),124.99(C-6'),123.46(C-1'),118.43(C-9),117.24(C-2'),116.14(C-5'),114.58(C-4),113.03(C-10),112.04(C-5),101.69(C-1"),77.44(C-3"),75.85(C-5"),73.35(C-2"),69.76(C-4"),60.73 (C-6"). The data are basically consistent with the data reported in the literature [ Zhao ai Hua et al, a new chalcone glycoside in Bidens pilosa, Yunnan plant research 2004,26(1): 121-.]And is identified as echinacoside.
The coreopsis tinctoria extract (CTH) sample containing echinacoside can be obtained by adding a maritin metabolite sample with required content into a coreopsis tinctoria primary extract according to requirements, uniformly mixing, and further drying.
Example 3: in vitro intestinal flora metabolic analysis of Helichrysum extract containing echinacoside
The experimental method comprises the following steps: fresh excrement of 5 normal SD rats is taken, smashed and stirred evenly according to the proportion of 1g excrement and 10mL physiological saline, homogenate is centrifuged for 10min at 500rmp in a centrifuge, and supernatant is taken to obtain the intestinal flora solution. Respectively sucking 200 mul of sample solution (3 mg/ml) and 200 mul of intestinal flora solution, sealing in an EP tube, diluting normal saline to 1ml, incubating in a 37 ℃ water bath at constant temperature, taking out the EP tube at a preset time point, adding 1ml of methanol to stop reaction, centrifuging, filtering supernatant, and detecting by high performance liquid chromatography.
The experimental results are as follows: the flavonoliside, Marinoside and echinacoside are rapidly and completely metabolized (2-6h) in intestinal flora to corresponding aglycone isoocannin, ocannin and echinacoside, and are completely metabolized in 24 h. The ingredients in the total flavonoids of coreopsis tinctoria are very complex, and under the action of intestinal flora, the main ingredients of the coreopsis tinctoria glycosides and malinosides are metabolized into corresponding aglycones, but the metabolic rate is greatly reduced. The results show that the intestinal flora can effectively utilize functional substances such as flavonoid glycoside in the coreopsis tinctoria extract containing echinacoside.
Example 4: metabolism analysis of in vitro intestinal flora by coreopsis tinctoria extract containing echinacoside
The experimental method comprises the following steps: fresh feces of 5 normal SD rats are taken, smashed and stirred uniformly according to the proportion of 1g feces to 10mL of physiological saline, homogenized in a centrifuge with 500rmp for 10min, 90 mu l of supernatant is taken, and 9mL of physiological saline is added, thus obtaining the dilute solution of the intestinal flora. Adding 9mL of CTH-1 sample solution in example 1 of 0, 1, 2 and 4mg/mL respectively, culturing in an anaerobic liquid culture medium at 37 ℃ for 24h, diluting the culture solution by a 10-fold-multiple dilution method, inoculating to a corresponding selective culture medium, culturing in a 37 ℃ incubator for 24h, counting the colony Count (CFU) in each solid culture medium, and detecting the change of the numbers of bifidobacteria, lactobacilli and escherichia coli in each group of culture solution after 24h of culture. The results are shown in Table 1.
Table 1 number of intestinal flora at each dose after 24 hours of culture (lgCFU/g,
n＝3)
note: p < 0.01 compared to blank; p < 0.05.
The experimental results are as follows: after the CTH-1 and the intestinal flora are co-cultured for 24 hours, both the lactobacillus and the bifidobacterium are obviously increased, and the escherichia coli is reduced. The results indicate that CTH has prebiotic effect.
Example 5: in vivo digestive tract metabolism analysis of Helichrysum extract containing echinacoside
To further determine the in vivo metabolism of the cedarwood flavonoids, 0, 0.5, 1, 2, 4h plasma samples, and 4h contents of stomach, small intestine, and large intestine were collected from normal SD rats after gavage of CTH-1 sample (200mg/kg) of example 1, and analyzed for major components and related metabolites using HPLC-DAD and UPLC-TOFMS/MS. UPLC-TOFMS/MS conditions: the Shimadzu LC-30A liquid phase system is connected with an AB5600+ mass spectrometer, an Analyst TF 1.6 workstation (Sciex, USA), an ACQUITY UPLC HSS T3 chromatographic column (2.1mm x 150mm,1.8 μm) is adopted, 0.1% formic acid is used as phase A, acetonitrile is used as phase B, 0-6min and 16% B are adopted; 6-15min, 16-30% B; 15-20min, 30-90% B, 40 ℃ column temperature, 0.3mL min-1 flow rate and 5 mul sample injection volume. The results are shown in Table 2.
TABLE 2 CTH-1200mg/kg) major metabolites in rats orally administered for 4h
As a result: after a single gavage administration of the asteriscus cinerarius extract containing echinacoside for 4h, the metabolism in the stomach of rats is not obvious (data not shown); as can be seen from the data in Table 2, three flavonoid glycosides in the small intestine contents are rapidly metabolized into corresponding aglycons of isocarboxannin, oxycainin and echinacon at 4h, and the compounds 1 and 3 are also converted into glucuronic acid conjugates and sulfate conjugates of the aglycons; glucuronic acid conjugate of corresponding compound 1, 3 aglycone is mainly detected in blood sample; glucuronic acid conjugates and sulfate conjugates of corresponding aglycones of the compounds 1 and 3 are mainly detected in the large intestine. The result shows that 3 flavonoid glycosides in the coreopsis tinctoria extract containing echinacoside are the main effective substances of coreopsis tinctoria, wherein the compounds 1 and 3 are mainly used in blood in the form of aglycon glucuronic acid metabolites; meanwhile, the sulfate conjugate of aglycone of the compound mainly stays in the intestinal tract; echinacoside is mainly utilized in the intestinal tract in the form of its aglycone; these components work together by regulating the metabolism of the intestinal flora.
As can be seen from the above examples, the Helichrysum deciduous extract containing echinacoside of the present invention has a definite intestinal flora regulating effect. The coreopsis tinctoria extract and the flavonoliside and the maliside separated from the coreopsis tinctoria extract have definite effects of regulating blood fat, reducing blood sugar, reducing blood pressure and the like. The invention unexpectedly discovers that echinacoside is one of in-vivo active ingredients in coreopsis tinctoria, and the content of the active ingredients can be effectively improved by the newly discovered preparation process of the coreopsis tinctoria extract, so that the coreopsis tinctoria extract containing the echinacoside can be applied to the preparation of functional foods for regulating related intestinal flora, regulating blood fat, reducing blood sugar and reducing blood pressure metabolic diseases.
Claims (4)
1. A preparation method of a coreopsis tinctoria extract containing echinacoside is characterized by comprising the following steps: obtaining a maroside-containing snow chrysanthemum primary extract solution, adjusting the pH value to 5-14, preserving the temperature at 30-100 ℃ for 0.5-10 h, neutralizing until the pH value is 3-5, concentrating, and drying to obtain a sea chrysanthemum extract, wherein the preparation method of the maroside-containing snow chrysanthemum primary extract solution comprises the following steps: weighing dry coreopsis tinctoria flowers, carrying out reflux extraction on the dried coreopsis tinctoria flowers for 2 times by using 75% ethanol which is 20 times of the amount of the obtained reflux extraction for 1 hour each time, combining extracting solutions of the two times, filtering, carrying out reduced pressure concentration to recover ethanol, adding a proper amount of water for dilution, refining the obtained product by using an AB-8 resin column, sequentially eluting the obtained product by using water and 75% ethanol, collecting an eluting part of the 75% ethanol, and concentrating to obtain a coreopsin-containing coreopsis tinctoria primary extract solution, wherein the content of the marroside in the marroside-containing coreopsis tinctoria primary extract solution is more than 10%, the content of the echinacoside in the coreopsis tinctoria extract is containing echinacoside is 5-50%, and the coreopsis tinctoria extract containing the echinacoside contains the unorin and the marroside.
2. The method for preparing a Helichrysum cinerariifolium extract containing echinacoside according to claim 1, wherein: the echinacoside in the plains coreopsis extract containing echinacoside is obtained by converting marioside.
3. The method for preparing a Helichrysum cinerariifolium extract containing echinacoside according to claim 1, wherein: adjusting the pH value to 6-12, and preserving the temperature at 35-80 ℃ for 0.5-10 h.
4. Use of a Helichrysum cinerariifolium extract containing echinacoside, prepared according to any one of claims 1 to 3, for the preparation of a functional food for regulating intestinal flora.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810653577.0A CN108783457B (en) | 2018-06-22 | 2018-06-22 | Preparation method and application of coreopsis tinctoria extract containing echinacoside |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810653577.0A CN108783457B (en) | 2018-06-22 | 2018-06-22 | Preparation method and application of coreopsis tinctoria extract containing echinacoside |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN108783457A CN108783457A (en) | 2018-11-13 |
| CN108783457B true CN108783457B (en) | 2021-08-03 |
Family
ID=64084695
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810653577.0A Active CN108783457B (en) | 2018-06-22 | 2018-06-22 | Preparation method and application of coreopsis tinctoria extract containing echinacoside |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108783457B (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102048786A (en) * | 2010-12-09 | 2011-05-11 | 新疆维吾尔自治区药物研究所 | Preparation and application of coreopsis extract |
| CN103222996A (en) * | 2013-05-15 | 2013-07-31 | 顾海 | Coreopsis tinctoria refined extract and medical application thereof |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2961398B1 (en) * | 2010-06-16 | 2013-02-15 | Oreal | COSMETIC USE OF A NATURAL EXTRACT FROM RED BEET PEEL, COMPOSITION COMPRISING THE EXTRACT AND A METAL DERIVATIVE, AN OXIDIZING AGENT AND AN ALKALINIZING AGENT |
| CN102764285B (en) * | 2012-08-01 | 2014-09-24 | 乌鲁木齐三高和药业有限公司 | Coreopsis tinctoria extract |
| CN103030993A (en) * | 2012-11-10 | 2013-04-10 | 新疆维吾尔自治区中药民族药研究所 | Process method for extracting coreopsis tinctoria nutt food colorant |
| CN103830301A (en) * | 2012-11-26 | 2014-06-04 | 北京健旭康技术有限公司 | Flos chrysanthemi with liver tonifying function and application thereof |
| CN104173400B (en) * | 2014-07-02 | 2018-01-02 | 苏州大学 | A kind of coreopsis tinctoria extract and its application |
| CN104996652A (en) * | 2015-06-01 | 2015-10-28 | 新疆生命核力高科股份有限公司 | Sanvitalia procumbens beverage and processing method thereof |
-
2018
- 2018-06-22 CN CN201810653577.0A patent/CN108783457B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102048786A (en) * | 2010-12-09 | 2011-05-11 | 新疆维吾尔自治区药物研究所 | Preparation and application of coreopsis extract |
| CN103222996A (en) * | 2013-05-15 | 2013-07-31 | 顾海 | Coreopsis tinctoria refined extract and medical application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN108783457A (en) | 2018-11-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101279964B (en) | Guaiane type sesquiterpenes, preparation and medical use thereof | |
| US10196417B2 (en) | Baicalin magnesium compound and its preparation method and application | |
| CN108191931B (en) | Three new compounds in Xinjiang peony and health care and medical application thereof | |
| KR100465113B1 (en) | Composition comprising an extract of Bambusoideae plant or tricin isolated therefrom | |
| CN104490894B (en) | The preparation method of Spermacoce latifolia triterpenoid and its preparing the application in glycosidase inhibitor | |
| CN111440157B (en) | Method for simultaneously separating schaftoside, vitamin adopted-2 and ecdysone and application thereof | |
| CN108783457B (en) | Preparation method and application of coreopsis tinctoria extract containing echinacoside | |
| CN101724008A (en) | Marsdenia tenacissima C21 steroidal glycoside converted product and preparation method and application thereof | |
| CN101723997A (en) | Puerarin glycosylation derivative, medicine compound, preparation method and application thereof | |
| CN113004299B (en) | Xanthone compound in mangosteen bark for reducing postprandial blood sugar, and extraction method and application thereof | |
| CN105796560A (en) | Ciprofloxacin medicine composition and application thereof to biological medicine | |
| CN111228279B (en) | Application of novel loquat leaf sesquiterpene glycoside in alleviating lipid deposition of liver cells | |
| CN110563688B (en) | Benzopyran compounds with anti-complement activity and application thereof | |
| KR100490799B1 (en) | Food comprising an extract of bambusoideae plant or tricin isolated therefrom | |
| CN114685573A (en) | Flavonoid glycoside compound separated from herba Aconiti Bonga and using quercetin as aglycone and application thereof | |
| CN114685578A (en) | Flavonoid glycoside compound separated from herba Aconiti Bonga and using kaempferol as aglycone, and its application | |
| CN107840814B (en) | Monocyclic diterpene compound cassipourol and preparation method thereof and the purposes in pharmacy | |
| CN110922444A (en) | Panaxadiol type triterpenoid saponin with anti-inflammatory activity | |
| CN105198954B (en) | C in CAULIS MARSDENIAE TENACISSIMAE21Steroid and its preparation method and application | |
| CN104083348A (en) | Applications of four kaurane diterpene compounds in preparation of glycosidase inhibitor medicines | |
| CN102391335A (en) | Isopentene flavonol glycoside derivative and preparation method and application thereof | |
| CN105753915B (en) | Caffeoyl benzyl carbinol glycoside compound and preparation method thereof and its application in anti-virus B hepatitis drug | |
| Bai et al. | Seven undescribed compounds from the flower heads of Helianthus annuus L. | |
| CN102988342B (en) | Application of cyclo-icaritin aglycone in preparation of anti-inflammatory and antimicrobial medicaments | |
| CN103211831B (en) | Flavone c-glycosides is preparing the application in cox 2 inhibitor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |